Table 1

Baseline characteristics of MISTIE-III patients with intraventricular haemorrhage, stratified by treatment group

Characteristicsn (%)P value*
MISTIE group (n=146)SMC group (n=164)
Age, mean (SD), years60.7 (11.6)61.6 (13.0)0.50
Sex
 Female48 (32.9)69 (42.1)0.10
 Male98 (67.1)95 (57.9)
Race and ethnicity†
 Black26 (17.8)27 (16.5)0.43
 Hispanic/Latino25 (17.1)26 (15.9)
 White88 (60.3)96 (58.5)
 Other‡7 (4.8)16 (10.4)
Hypertension140 (95.9)157 (95.7)0.94
Diabetes44 (30.1)49 (29.9)0.96
Hyperlipidaemia52 (35.6)66 (40.2)0.40
Tobacco use25 (17.1)26 (15.9)0.76
Cocaine use4 (2.7)7 (4.3)0.47
Previous anticoagulant use10 (6.8)8 (4.9)0.46
Previous antiplatelet use45 (30.8)54 (32.9)0.69
Clinical severity factor
 GCS score at randomisation§10 (8, 12)10 (8, 13)0.67
ICH location
 Lobar45 (30.8)70 (42.7)0.03
 Deep101 (69.2)94 (57.3)
Parenchymal ICH volume on admission, mL§46.8 (33.2–59.8)45.8 (34–59.5)0.87
IVH volume on admission, mL§1.1 (0–5.2)0.6 (0–3.8)0.24
Parenchymal ICH volume at stability, mL§51.6 (39.9–64.4)50.3 (38.4–62.8)0.38
IVH volume at stability, mL§2.2 (0.7–5.9)2.0 (0.5–4.9)0.39
End-of-treatment parenchymal ICH volume, mL§15.3 (8.9–21.8)46.9 (37.1–60.6)<0.0001
End-of-treatment IVH volume, mL§0.9 (0.3–2.7)1.3 (0.3–3.0)0.29
EVD use33 (22.6)25 (15.2)0.10
Time interval from ictus to end-of-treatment CT scan, hours§125.5 (104–157.5)116 (103–127)0.0001
Number of doses of study agent§4 (3, 7)n/an/a
Time interval from ictus to first dose of study agent, hours§71 (56–82)n/an/a
  • *P<0.05 was considered statistically significant.

  • †Race and ethnicity were investigator reported in the MISTIE-III trial.

  • ‡Other included Asian, Native American, Native Hawaiian or other Pacific Islander.

  • §Indicates values presented as median (IQR).

  • EVD, external ventricular drainage; GCS, Glasgow Coma Scale; ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; MISTIE-III, Minimally Invasive Surgery plus Alteplase for Intracerebral Hemorrhage Evacuation Phase III; SMC, standard medical care.